/
We are a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. We have built a business focused on developing and commercializing innovative therapeutics that we believe serve as a foundation for future growth, including by contributing net product revenue to support the development and advancement of our robust pipeline of mid…
Operating margin is thin at 9.95%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 47.5% YoY with margins expanding 41.5pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$232M
▲ +47.5% YoY
Net Income (TTM)
-$21M
▲ +92.3% YoY
Op. Margin
2.28%
▲ +41.5pp YoY
ROIC
4.92%
▲ +116.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$60M
▲ +266.4% YoY
Op. Cash Flow (TTM)
$60M
▲ +267.2% YoY
Net Debt
-$112M
Net Cash Position
Cash & Equiv.
$163M
5Y CAGR: -4.3%
Continue Research